# Robotic vs. Laparoscopic Surgery for Rectal Cancer: What a 56-Study Analysis of 27,648 Patients Found Robotic surgery for rectal cancer produced more complete tissue specimens than laparoscopic (keyhole) surgery. Robotic surgery also left fewer cancer cells at the cut end of the bowel. This finding comes from a review of 56 studies covering 27,648 patients. The rate of cancer cells at the outer margin of the removed tissue was nearly identical between the two techniques, as was the risk of the cancer returning locally. However, the authors caution that the overall certainty of the evidence is low. Patients in the robotic group were more often the harder cases. These harder cases included men, tumours lower in the rectum, and patients who had received chemotherapy and radiation before surgery. # Robotic versus laparoscopic TME for rectal cancer: meta-analysis of pathological quality indicators. ## Table of Contents - Key Points - Background: Why Tissue Quality Matters in Rectal Cancer - What Are TME, Robotic Surgery and Laparoscopic Surgery? - How the Researchers Conducted the Review - Which Studies Were Included - Who Was in Each Group: Baseline Characteristics - Key Findings: Quality of the Removed Tissue - Key Findings: Local Recurrence of Cancer - What Happened When Only Randomised Trials Were Analysed - Clinical Implications: What This Means for Patients - Limitations: What This Study Could Not Prove - Recommendations for Patients - Frequently Asked Questions - Source Information ## Key Points - In a review of 56 studies covering 27,648 patients, robotic surgery produced more complete TME specimens than laparoscopic surgery, but the overall certainty of the evidence was low. - Circumferential resection margin positivity was nearly identical between robotic and laparoscopic surgery across all 56 studies, covering 27,592 patients. - Robotic groups contained more men, more low tumours and more patients given pre-operative chemoradiotherapy, a selection bias the authors say favoured laparoscopic surgery. - In 14 studies covering 8,283 patients, significantly fewer robotic patients had cancer cells at the distal resection margin, the cut end of the bowel below the tumour. - Local recurrence data from 23 studies covering 6,360 patients showed a trend favouring robotic surgery that did not reach statistical significance in the main analysis. ## Background: Why Tissue Quality Matters in Rectal Cancer Rectal cancer surgery has one main goal beyond removing the tumour: taking out the cancer with a clean, intact envelope of fatty tissue around it. That fatty envelope is called the **mesorectum**, and the operation that removes it whole is called **total mesorectal excision (TME)** — the complete removal of the rectum together with its surrounding fatty tissue and blood supply. TME was introduced by Heald and colleagues and has become the reference standard for rectal cancer surgery. When combined with chemotherapy and radiation, it gives excellent rates of cancer control for tumours in the middle and lower rectum — the part of the bowel closest to the anus. Surgical teams now judge the quality of their work by three measurements: - **Complete TME** — the fatty envelope came out in one unbroken piece, without tears or holes. - **Circumferential resection margin (CRM)** — the outer, circular edge of the removed tissue. A "negative" or "clear" margin means no cancer cells reached that edge. - **Distal resection margin (DRM)** — the cut end of the bowel below the tumour. Again, a negative margin means no cancer cells at that edge. The authors note that achieving a complete specimen plus negative CRM and DRM in more than 90% of cases is now widely recognised. This is the mark of an excellent rectal cancer centre. In other words, roughly 9 in 10 patients should get all three results. Surgery for rectal cancer has evolved. Open surgery (a large cut in the abdomen) was the original approach. **Laparoscopic surgery** — often called keyhole surgery — came next. It uses several small cuts and a camera. Compared with open surgery, laparoscopic TME has shown several short-term advantages: - Less blood loss - Faster recovery after the operation - Shorter hospital stay But laparoscopic surgery has real drawbacks in the rectum. The pelvis is a narrow, rigid space. Laparoscopic instruments are straight, have limited ability to bend and twist, and the camera view can be unstable. The learning curve is steep — meaning surgeons need many operations before they become reliable. Some randomised controlled trials (RCTs) failed to prove that laparoscopic surgery was at least as good as open surgery. RCTs are the strongest type of medical study, where patients are randomly assigned to treatments. **Robotic surgery** was developed to address those limitations. The surgeon sits at a console and controls robotic arms that bend and rotate inside the patient, with a stable, magnified 3D view. This combines faster recovery with steadier, more comfortable dissection in the narrow pelvis. In theory, that should produce better specimens. Yet robotic surgery is not universally adopted. Two arguments are made against it. First, it costs more. Second, the evidence of superiority for cancer outcomes has not been solid. The pivotal **ROLARR trial** found similar TME completeness and CRM positivity rates for robotic and laparoscopic surgery. However, a later secondary analysis called **ROLARR 2** suggested those results might have been affected by the robotic learning curve. Once surgeons had performed more than 40 robotic cases, the tissue outcomes (TME completeness and CRM positivity) appeared to favour robotic surgery — though not always to a statistically significant degree. This is the debate the current study set out to settle. ## What Are TME, Robotic Surgery and Laparoscopic Surgery? A quick clarification of terms, since they appear throughout this article. **TME (total mesorectal excision)** removes the entire rectum plus the fatty tissue and lymph nodes around it, down to the pelvic floor. It is used for tumours in the middle and lower rectum. It is different from a **partial mesorectal excision (PME)** or a **high anterior resection (HAR)**, which remove less tissue and are used for higher tumours. This review deliberately excluded those lesser operations — a key point, because mixing them in is a major source of confusion in earlier reviews. **Laparoscopic TME** is performed through several small incisions, with the surgeon's hands on long instruments outside the body. **Robotic TME** is also minimally invasive, but the surgeon's hands control robotic arms through a console. In this review, all robotic operations used the da Vinci Si or Xi system. Both groups used the same standard TME technique — the difference was the tool, not the operation. **Neoadjuvant chemoradiotherapy** means chemotherapy plus radiation given *before* surgery, to shrink the tumour. "Neoadjuvant" simply means "given first." ## How the Researchers Conducted the Review This was a **meta-analysis** — a study that pools the results of many separate studies into one combined answer. Combining studies gives more patients and more statistical power than any single trial. The researchers registered their plan in advance with PROSPERO, an international database of systematic review protocols (study ID CRD420251024701). Registering the plan in advance prevents reviewers from cherry-picking results afterwards. They searched two large medical databases, PubMed and EMBASE, for all studies comparing robotic with laparoscopic TME. They also hand-searched the reference lists of relevant reviews. The final search was run on 30 May 2025. The search terms combined "robotic," "laparoscopic," and "rectal cancer OR total mesorectal excision OR anterior resection." They followed the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). PRISMA is the internationally accepted standard for reporting this type of research. They also used a framework called PICOS to define exactly which patients, interventions, comparisons, outcomes and study designs would be allowed. To be included, a study had to: 1. Be written in English. 1. Compare robotic with laparoscopic TME directly. 1. Report pathological outcomes (the laboratory findings on the removed tissue). 1. Report TME quality or CRM positivity. Studies were excluded if they compared robotic surgery with open surgery. Studies were excluded if they mixed in partial mesorectal excision or high anterior resection. Studies were excluded if they lacked comparative data. Studies were excluded if they failed to report tumour characteristics between groups. The last exclusion applies because that creates an unacceptable risk of selection bias (where the two groups differ in ways that distort the comparison). Two reviewers independently screened titles and abstracts, then reviewed the full texts of potentially eligible studies. Disagreements were settled by discussion until consensus was reached. Study quality was graded with three standard tools: ROB2 for randomised trials, ROBINS-I for observational studies, and GRADE for overall certainty of evidence. The researchers also attempted to contact authors of excluded studies to clarify data, but the response rate was unsatisfactory. The statistical approach matters here. For outcomes with two possible results (such as "margin positive" or "margin negative"), the researchers calculated pooled **odds ratios (ORs)** with 95% confidence intervals. An odds ratio compares how likely an event is in one group versus another. An OR of 1.00 means no difference. An OR above 1.00 means the event is more common in the first group; below 1.00 means it is less common. A **95% confidence interval (CI)** is the range in which the true answer probably lies. If that range crosses 1.00, the result is not statistically significant — it could plausibly be due to chance. The researchers used **random-effects models** as the primary method for all outcomes. Random-effects models assume that different studies are measuring slightly different things and account for that variation. They used fixed-effects models only in pre-specified sensitivity analyses, when variation between studies was low. They measured how much the studies disagreed with each other using Cochran's Q test and the **I² statistic**. By convention, I² values of 25%, 50% and 75% represent low, moderate and high heterogeneity (inconsistency between studies). Where at least ten studies contributed data to an outcome, they inspected **funnel plots** — graphs used to detect publication bias, the tendency for positive results to be published more often than negative ones. They also ran a **meta-regression** to test whether tumour height (distance from the anal verge) explained differences in distal margin results. All analyses used RevMan v5.3 and MedCalc v23.2.0 software. ## Which Studies Were Included The initial search found 3,731 studies. After removing duplicates and clearly irrelevant papers, 127 full texts were assessed in detail. Of those, 56 studies met the inclusion criteria and were analysed. Notably, 27 studies were excluded because TME was not the only procedure performed in both groups — they had mixed in partial mesorectal excision or high anterior resection. Excluding these eliminated a major source of inconsistency. Publication years ranged from 2013 to 2025. The 56 studies included **4 randomised controlled trials** and **19 case-matched studies** (studies in which each robotic patient is paired with a similar laparoscopic patient on key characteristics). The remainder were other comparative observational studies. The total patient population was **27,648**: - **Robotic group:** 10,629 patients - **Laparoscopic group:** 17,019 patients All robotic procedures used the da Vinci Si or Xi system, and standard TME technique was followed in both groups. The mean age was 61.9 years (standard deviation 10.2) in the robotic group and 62.3 years (SD 10.3) in the laparoscopic group. Mean body mass index (BMI, a measure of weight relative to height) was 24.5 (SD 3.1) and 24.4 (SD 3.2) respectively — essentially identical. Three of the included trials deserve special mention because they are the largest randomised comparisons: **ROLARR**, **REAL** and **COLRAR**. This review is described as the most up-to-date synthesis available and is the first to include the recent REAL and COLRAR randomised trials. ## Who Was in Each Group: Baseline Characteristics This section matters more than it might first appear. If the robotic group contained harder cases, then any advantage seen in that group is more impressive. And that is exactly what the data showed. ### Gender Fifty-five studies covering 27,580 patients reported gender. There were **fewer male patients in the laparoscopic group** (OR 1.085, 95% CI 1.029–1.144, p = 0.003). This means the robotic group had a higher proportion of men, whose narrower pelvises make rectal surgery more difficult. There was no significant inconsistency between studies (Chi² = 64.44, df = 53, p = 0.134, I² = 17.7%). The funnel plot showed no significant publication bias (p = 0.436, 95% CI 0.318–0.726). ### Body Mass Index Forty-six studies covering 14,250 patients compared mean BMI. The two groups were similar, with a mean difference of 0.0519 (95% CI 0.008–0.112, p = 0.090). There was significant inconsistency between studies (Chi² = 108.1, df = 45, p < 0.0001, I² = 58.39%). No publication bias was detected (p = 0.223, 95% CI 0.369–1.538). ### Tumour Stage T3/T4 Thirty-two studies covering 12,918 patients reported the proportion of **pT3/T4 tumours** — cancers that have grown through the bowel wall or into nearby structures. "pT" refers to the pathologist's staging of the removed tumour; T3 and T4 are more advanced local stages. There was **no significant difference** between groups (OR 0.906, 95% CI 0.783–1.049, p = 0.186), though there was significant inconsistency between studies (Chi² = 79.98, df = 31, I² = 61.24%). No significant publication bias was found (p = 0.532, 95% CI 1.012–1.918). ### Lymph Node Involvement (N+) Thirty studies covering 8,988 patients reported whether lymph nodes contained cancer (N positive or negative). The groups were **essentially identical** (OR 0.997, 95% CI 0.833–1.193, p = 0.971), with significant inconsistency between studies (Chi² = 96.54, df = 29, I² = 69.96%). No significant publication bias was found (p = 0.086, 95% CI 0.212–3.009). ### Neoadjuvant Chemoradiotherapy Fifty-two studies covering 26,643 patients (10,069 robotic versus 16,574 laparoscopic) reported how many patients received chemotherapy and radiation before surgery, regardless of the specific schedule used (short-course, long-course, or total neoadjuvant therapy). **Significantly more robotic patients received pre-operative treatment** (OR 1.382, 95% CI 1.181–1.617, p < 0.001), with significant inconsistency between studies (Chi² = 208.91, df = 42, I² = 79.90%). No significant publication bias was found (p = 0.872, 95% CI 1.024–1.203). ### Distance From the Anal Verge Thirty-three studies covering 7,701 patients (3,854 robotic versus 3,847 laparoscopic) compared how far the lower edge of the tumour sat from the anal verge. **Robotic tumours were significantly lower** — closer to the anus — by a mean difference of 0.125 cm (95% CI 0.007–0.242, p < 0.037). There was significant inconsistency between studies (Chi² = 187.90, df = 32, I² = 82.97%). No notable publication bias was detected (p = 0.904, 95% CI 1.991–2.241). Taken together, these baseline findings show a clear pattern: the robotic groups contained more men, more low-lying tumours, and more patients who had received pre-operative chemotherapy and radiation. These are precisely the technically demanding cases. The authors describe this as a selection bias that would favour laparoscopic surgery — meaning robotic surgery was starting from behind. ## Key Findings: Quality of the Removed Tissue ### Completeness of TME Twenty-seven studies covering 7,065 patients (3,356 robotic versus 3,709 laparoscopic) reported the quality of the TME specimen, classified as complete or incomplete (or by the layers visible: mesorectal, intramesorectal, or muscularis propria). **Robotic surgery produced significantly more complete TME specimens** (OR 1.497, 95% CI 1.229–1.822, p < 0.001), with moderate inconsistency between studies (Chi² = 36.60, df = 25, I² = 31.70%). The funnel plot showed no significant asymmetry suggesting publication bias (p = 0.1334, 95% CI 0.242–1.717). In plain terms: patients having robotic surgery were more likely to have their tumour removed inside an unbroken fatty envelope. This is the single most important technical marker of a high-quality rectal cancer operation. A higher odds ratio means better odds of a complete specimen. An odds ratio of about 1.50 suggests roughly 50% higher odds of completeness in the robotic group, though the true value could range from about 23% to 82% higher based on the confidence interval. ### Circumferential Resection Margin (CRM) All 56 studies, covering 27,592 patients (10,604 robotic versus 16,988 laparoscopic), compared CRM positivity. This is the outer margin — the edge most closely linked to whether cancer returns in the pelvis. There was **no significant difference** between the two approaches (OR 0.930, 95% CI 0.774–1.118, p = 0.441), and inconsistency between studies was low (Chi² = 68.61, df = 51, I² = 25.67%). The funnel plot showed no significant publication bias (p = 0.988, 95% CI −0.453 to 0.446). This is a genuinely important negative finding. On the measurement most strongly tied to local cancer control, robotic and laparoscopic surgery performed equally well. ### Distal Resection Margin (DRM) Fourteen studies covering 8,283 patients (3,381 robotic versus 4,902 laparoscopic) reported DRM positivity — cancer cells at the cut end of the bowel, below the tumour. **Significantly fewer robotic patients had a positive distal margin** (OR 0.678, 95% CI 0.477–0.965, p = 0.031). Notably, there was **zero inconsistency between studies** (Chi² = 8.55, df = 13, I² = 0%). No significant publication bias was detected (p = 0.355, 95% CI 0.499–1.289). An odds ratio of 0.68 means the odds of a positive distal margin were about 32% lower in the robotic group. That is a meaningful advantage. Achieving clear distal margins in low rectal cancers can be the difference between keeping the anal sphincter and needing a permanent stoma. A permanent stoma is an opening in the abdomen for waste to leave the body. To check whether this result was simply because robotic surgeons operated on different tumours, the researchers ran a meta-regression using the difference in tumour height between groups as a variable. It found **no significant association** between tumour height and the size of the distal margin benefit (β = 0.24, standard error 0.69, p = 0.73). In other words, differences in tumour height did not explain the variation in results between studies. ## Key Findings: Local Recurrence of Cancer Twenty-three studies covering 6,360 patients (3,038 robotic versus 3,322 laparoscopic) reported how often the cancer came back in the pelvis (local recurrence). Mean follow-up was **46.50 ± 10.4 months** in the robotic group and **47.62 ± 14.2 months** in the laparoscopic group — roughly four years in both groups. There was a trend towards fewer recurrences after robotic surgery, most visible in the fixed-effects model (OR 0.757, 95% CI 0.600–0.955, p < 0.019). However, in the standard random-effects model — the researchers' pre-specified primary approach — the difference **did not reach statistical significance** (OR 0.751, 95% CI 0.539–1.045, p = 0.090), with low-to-moderate inconsistency between studies. Because the confidence interval crossed 1.00, the honest reading is this: recurrences may be less common after robotic surgery, but this review cannot prove it. The result is suggestive, not definitive. ## What Happened When Only Randomised Trials Were Analysed Randomised controlled trials are the strongest evidence because patients are assigned to treatments by chance, removing the selection bias that plagues observational studies. The researchers therefore repeated the analysis using only RCTs. The results shifted: - **TME completeness:** a trend towards better quality in the robotic group, but it did not reach statistical significance (OR 1.290, 95% CI 0.989–1.683, p = 0.061). - **CRM positivity:** a higher rate of positive circumferential margins in the laparoscopic group (OR 0.669, 95% CI 0.450–0.994, p = 0.047) — meaning robotic surgery had the advantage on this outcome in randomised data. This is a fascinating reversal. In the full pooled analysis of all 56 studies, CRM positivity was equal between groups. In the randomised-only analysis, robotic surgery came out ahead. It is a reminder that how you slice the data can change the answer, and the authors flag the low certainty of the evidence throughout. ## Clinical Implications: What This Means for Patients The authors draw three main conclusions. First, robotic TME is associated with higher specimen completeness and lower distal margin positivity than laparoscopic TME. Second, CRM positivity and local recurrence rates appear broadly similar. Third, and importantly, these findings should be interpreted cautiously because the certainty of the evidence is low. What does this mean in practical terms for someone facing rectal cancer surgery? - **Both operations are safe and effective.** The two techniques produced comparable results on the margin most linked to local cancer control (CRM) and on local recurrence. - **Robotic surgery may deliver a cleaner specimen.** More complete TME specimens and fewer positive distal margins suggest a technical edge in tight pelvic anatomy. - **The robotic advantage appeared despite harder cases.** Robotic groups contained more men, more low tumours and more patients who had pre-operative chemoradiotherapy — factors that normally make surgery more difficult. The authors describe this as a selection bias favouring laparoscopic surgery. - **Organ preservation may be more achievable.** Clearer distal margins in low rectal cancers matter because they improve the chances of avoiding a permanent stoma. The authors state their data support the use of robotics as a primary minimally invasive option for mid-to-low rectal cancer. That is a stronger position than many prior reviews have taken. They also explain why this review reached a different place than earlier work. Most research showing similar outcomes between the two techniques focused on operative and functional outcomes. These included conversion rates (switching to open surgery mid-operation), operating time, complications, sexual and urinary dysfunction, and patient-reported outcomes. Those outcomes might be expected to be comparable. This review focused exclusively on what the pathologist finds in the specimen, which is where a technical difference should show up. The review is also the first to include only TME procedures, excluding partial mesorectal excision and high anterior resections. Earlier reviews mixed these in, adding a major source of inconsistency. This review is described as the most up-to-date synthesis of pathological outcomes comparing the two approaches, and it incorporates the recent REAL and COLRAR randomised trials. ## Limitations: What This Study Could Not Prove The authors are candid about the weaknesses of their own work. Patients and clinicians should weigh these carefully. 1. **Low certainty of evidence.** The GRADE assessment showed the overall quality of evidence is low. The authors explicitly state their findings should be interpreted cautiously because of this. 1. **Most studies were not randomised.** Of the 56 studies, only 4 were randomised controlled trials. The rest were observational or case-matched, which cannot fully eliminate selection bias. 1. **Selection bias favoured laparoscopic surgery.** Robotic groups contained more men, lower tumours and more patients who had pre-operative chemoradiotherapy. This cuts both ways — it makes the robotic results look stronger, but it also means the two groups were not truly comparable. 1. **Substantial inconsistency between studies.** Heterogeneity was significant for several outcomes, including BMI (I² = 58.39%), T3/T4 stage (I² = 61.24%), lymph node status (I² = 69.96%), neoadjuvant therapy (I² = 79.90%) and distance from the anal verge (I² = 82.97%). 1. **Some outcomes came from few studies.** The distal margin finding rested on just 14 studies, and the TME completeness finding on 27. Local recurrence data came from 23 studies with only about four years of follow-up — long-term survival was not assessed. 1. **The learning curve issue.** As ROLARR 2 suggested, robotic outcomes improve after about 40 cases. Pooled results do not capture where individual surgeons sat on that curve. 1. **Publication bias cannot be fully excluded.** Funnel plots suggested no significant bias, but the researchers note the known limitations of these tests for binary outcomes and did not perform formal regression-based tests. 1. **Contact with authors was unsuccessful.** The response rate for clarifying unclear data was unsatisfactory, which may have left some studies out. One more consideration: costs. The authors note increased cost as an argument against wider robotic adoption, but this review did not analyse cost data. That remains a separate question for hospitals and health systems. ## Recommendations for Patients If you or a family member are facing surgery for rectal cancer, here is how to use this research. 1. **Ask about your surgeon's experience, not just the technology.** Pathological quality depends heavily on who operates. Ask how many rectal cancer TME procedures your surgeon performs each year and, for robotic surgery, how many they have completed. The research suggests performance improves after roughly 40 robotic cases. 1. **Ask which approach suits your tumour.** If your tumour sits in the middle or lower rectum, and especially if it is technically challenging, robotic surgery may offer an edge in specimen quality and distal margin clearance. For higher tumours or simpler anatomy, the difference may matter less. 1. **Ask about the three quality markers.** A good rectal cancer centre should be able to tell you its rates of complete TME, negative CRM and negative DRM. The benchmark referenced in this review is above 90% for each. 1. **Understand that both operations are acceptable.** This review did not find robotic surgery to be dramatically better overall. CRM positivity and local recurrence were broadly similar. If robotic surgery is not available locally, laparoscopic surgery remains a sound option. 1. **Do not delay treatment to wait for a specific platform.** Timing of surgery and completion of any pre-operative chemotherapy and radiation matter more than the choice of instrument. Neoadjuvant treatment was used in both groups in this review and is standard for many mid-to-low rectal cancers. 1. **Ask about sphincter preservation.** If avoiding a permanent stoma is important to you, discuss it directly. The lower distal margin positivity rate with robotic surgery may be relevant to that conversation. 1. **Choose a high-volume centre.** The review's quality benchmarks — complete TME, clear margins in more than 90% of cases — are achieved at experienced, specialised centres. The bottom line: robotic surgery shows a measurable advantage in the quality of tissue removed during rectal cancer surgery, particularly in technically difficult cases. But the evidence is not strong enough to declare it the winner for every patient. The best choice depends on your tumour, your surgeon's experience, and what is available where you are treated. ## Frequently Asked Questions ### What is total mesorectal excision (TME) and why does the quality of the removed tissue matter? TME removes the rectum together with its surrounding fatty envelope and blood supply. Surgical teams judge quality by three markers: a complete TME specimen, a negative circumferential resection margin, and a negative distal resection margin. Achieving all three in more than 90% of cases is widely recognised as the mark of an excellent rectal cancer centre. ### Does robotic surgery remove rectal cancer tissue more completely than laparoscopic (keyhole) surgery? In a review of 56 studies covering 27,648 patients, robotic surgery produced significantly more complete TME specimens than laparoscopic surgery (odds ratio 1.497). However, the authors caution that the overall certainty of this evidence is low, so the finding should be interpreted cautiously rather than taken as settled. ### Is the risk of cancer cells at the outer margin of the removed tissue different between robotic and laparoscopic surgery? Across all 56 studies covering 27,592 patients, there was no significant difference in circumferential resection margin positivity between robotic and laparoscopic surgery. This margin is the one most closely linked to whether cancer returns in the pelvis, so equal performance here is an important finding. ### Does robotic surgery reduce the chance of cancer coming back in the pelvis? In 23 studies covering 6,360 patients with roughly four years of follow-up, there was a trend towards fewer local recurrences after robotic surgery. But the trend did not reach statistical significance in the main analysis. The honest reading is that recurrences may be less common, but the review cannot prove it. ### Were the patients having robotic surgery similar to those having laparoscopic surgery? No. Robotic groups contained more men, more tumours lower in the rectum, and more patients who had received chemotherapy and radiation before surgery. These are technically demanding cases. The authors describe this as a selection bias that would favour laparoscopic surgery, meaning robotic surgery was starting from behind. ### What does it mean if a distal resection margin is positive, and did robotic surgery reduce this? The distal resection margin is the cut end of the bowel below the tumour; a positive margin means cancer cells reached that edge. In 14 studies covering 8,283 patients, significantly fewer robotic patients had a positive distal margin. Clearer distal margins in low rectal cancers may improve the chances of avoiding a permanent stoma. ### What should I ask my surgeon before choosing between robotic and laparoscopic surgery for rectal cancer? Ask how many rectal cancer TME procedures your surgeon performs each year and, for robotic surgery, how many they have completed, since performance appears to improve after roughly 40 robotic cases. Ask about the centre's rates of complete TME, negative circumferential margin and negative distal margin. Both operations are acceptable; do not delay treatment to wait for a specific platform. ### If I have rectal cancer and robotic surgery is recommended, when should I get a second opinion? A second opinion is worth considering when the recommended operation is robotic total mesorectal excision for a mid or low rectal tumour. This is particularly true if the tumour is technically difficult. Robotic surgery produced more complete specimens and fewer positive distal margins than laparoscopic surgery. Circumferential margin positivity and local recurrence were broadly similar. Pathological quality depends heavily on the surgeon's experience, with performance improving after roughly 40 robotic cases. An independent review can help confirm whether the approach and the surgical team suit your tumour. Diagnostic Detectives Network provides independent expert second opinions. ## Source Information **Original article title:** Robotic versus laparoscopic TME for rectal cancer: meta-analysis of pathological quality indicators. **Authors:** S. Morarasu, S. Lunca, C. Clancy, W. L. Ong, E. Morpurgo, G.-M. Dimofte **Journal:** Techniques in Coloproctology (2026) 30:69 **DOI:** https://doi.org/10.1007/s10151-026-03369-7 **Article type:** Review (meta-analysis) **Published:** 2026. Received 3 December 2025; accepted 17 May 2026. **Registry:** PROSPERO (International Prospective Register of Systematic Reviews), study ID CRD420251024701 **Funding and access:** Open access, © The Author(s) 2026 *This patient-friendly article is based on peer-reviewed research. It summarises the findings of a single meta-analysis and is not a substitute for individual medical advice. Discuss your treatment options with your own surgical and oncology team.* --- Publisher: Diagnostic Detectives Network (https://diagnosticdetectives.com) — independent multi-expert medical second opinions, worldwide, private-pay. Author byline: Anton Titov, MD, PhD. Contact: https://diagnosticdetectives.com/pages/contact Canonical page: https://diagnosticdetectives.com/products/robotic-vs-laparoscopic-surgery-for-rectal-cancer-what-a-56-study-analysis-of-27-648-patients-found